Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$8.31 USD
-0.28 (-3.26%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $8.30 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Income Statements
Fiscal Year end for Atara Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 9 | 64 | 20 | 0 | 0 |
Cost Of Goods | 9 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 64 | 20 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 276 | 344 | 361 | 309 | 296 |
Income After Depreciation & Amortization | -276 | -281 | -340 | -309 | -296 |
Non-Operating Income | 5 | 52 | 0 | 2 | 5 |
Interest Expense | 5 | 0 | 0 | 0 | 0 |
Pretax Income | -276 | -228 | -340 | -307 | -291 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -276 | -228 | -340 | -307 | -291 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -276 | -228 | -340 | -307 | -291 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -270 | -274 | -329 | -300 | -290 |
Depreciation & Amortization (Cash Flow) | 6 | 7 | 11 | 9 | 6 |
Income After Depreciation & Amortization | -276 | -281 | -340 | -309 | -296 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.24 | 4.08 | 3.75 | 2.96 | 2.05 |
Diluted EPS Before Non-Recurring Items | -65.25 | -68.25 | -90.75 | -103.75 | -141.75 |
Diluted Net EPS (GAAP) | -65.25 | -56.00 | -90.75 | -103.75 | -141.75 |
Fiscal Year end for Atara Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 28.64 | 27.36 | 4.25 | 2.14 | 0.96 |
Cost Of Goods | 4.63 | 1.99 | 3.16 | 2.62 | 2.90 |
Gross Profit | 24.01 | 25.37 | 1.09 | -0.48 | -1.94 |
SG&A, R&D, and Dept/Amort Expenses | 42.24 | 56.62 | 61.05 | 69.14 | 69.48 |
Income After SG&A, R&D, and Dept/Amort Expenses | -18.23 | -31.25 | -59.96 | -69.62 | -71.42 |
Non-Operating Income | 0.44 | 0.67 | 0.70 | 1.19 | 1.69 |
Interest Expense | 1.26 | 1.15 | 1.18 | 1.40 | 1.38 |
Pretax Income | -19.05 | -31.73 | -60.44 | -69.82 | -71.11 |
Income Taxes | 0.00 | 0.02 | 0.01 | -0.02 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -19.05 | -31.75 | -60.45 | -69.80 | -71.11 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -19.05 | -31.75 | -60.45 | -69.80 | -71.11 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 6.14 | 5.62 | 4.33 | 4.26 | 4.20 |
Diluted EPS Before Non-Recurring Items | -3.10 | -5.75 | -14.00 | -16.50 | -17.00 |
Diluted Net EPS (GAAP) | -3.10 | -5.75 | -13.75 | -16.50 | -17.00 |